BioArctic ABBRCTF 84 EBITDA Margin % is 51.34% as of Mar. 2026, which is 72% above its 10-year median of 29.83. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.29 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, BioArctic AB ranks better than 91.32% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioArctic AB's EBITDA for the
three
months ended in Mar. 2026 was $24.1 Mil. BioArctic AB's Revenue for the
three
months ended in Mar. 2026 was $47.0 Mil. Therefore, BioArctic AB's EBITDA margin for the quarter that ended in Mar. 2026 was 51.34%.
BioArctic AB (OTCPK:BRCTF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioArctic AB EBITDA Margin % Related Terms
BioArctic AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioArctic AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRCTF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioArctic AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioArctic AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB (BRCTF) has a EBITDA Margin % of 51.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioArctic AB and its competitors. This is 72% above median its historical median of 29.83. According to the industry distribution chart, BioArctic AB ranks #82 out of 945 companies in the Biotechnology industry, placing it in the top 8.7%.
Is BioArctic AB's EBITDA Margin % too high?
BioArctic AB's current EBITDA Margin % of 51.34% is 72% above median its 10-year median of 29.83. Based on the distribution chart, BioArctic AB ranks #82 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #82 out of 945 companies for EBITDA Margin %. This places BioArctic AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioArctic AB and its competitors. BioArctic AB's current EBITDA Margin % is 51.34%, which is 72% above median its own 10-year median of 29.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.29, compared to a current price of $35.00 — trading 29% below its estimated fair value. The current EBITDA Margin % is 51.34%, which is 72% above median its 10-year median of 29.83. BioArctic AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current EBITDA Margin % is 51.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (BRCTF) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of $35.00 is trading 29% below its estimated GF Value™ of $49.29.
GuruFocus considers BioArctic AB to be Modestly Undervalued.
Key valuation signals for BRCTF:
EBITDA Margin %: 51.34% (72% above median its 10-year median of 29.83)
GF Value™: $49.29 vs. price of $35.00 (29% below fair value)
No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score
Get the complete analysis for BRCTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRCTF has been successfully added to your 
